Registered clinical trials of gene therapy in haemophilia

The following clinical trials of gene therapy in haemophilia are currently registered on ClinicalTrials.gov and/or the EU Clinical Trials Register

Title

 

ClinicalTrials.gov Identifier

 

Phase Haemophilia Vector/Transgene Status* Sponsor Dates Patients
An open label dose-escalation study of a self-complementary adeno-associated viral vector (scAAV 2/8-LP1-hFIXco) for gene transfer in hemophilia B

(N Engl J Med 2011;365:2357-65; N Engl J Med 2014;371:1994-2004)

NCT00979238 I B scAAV 2/8-LP1-hFIXco Active, not recruiting St Jude Children’s Research Hospital Start Feb 2010

 

Completion Dec 2018 (2032 for secondary outcomes)

 

N = 14
A Phase I/II, open-label, uncontrolled, single-dose, dose-ascending, multi-centre trial investigating an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) administered to adult patients with severe or moderately severe hemophilia B

(Blood 2018;131:1022-1031)

NCT02396342 I/II B AAV5-hFIX

 

(AMT-060)

Active, not recruiting UniQure Start May 2015

 

Completion 2021

N = 10
A Phase 1/2, dose-escalation safety, tolerability and efficacy study of BMN 270, an adenovirus-associated virus vector-mediated gene transfer of human factor VIII in patients with severe haemophilia A

(N Engl J Med 2017;377:2519-30)

NCT02576795 I/II A valoctocogene roxaparvovec Active, not recruiting Biomarin Start August 2015

 

Completion 2022

N = 15
Gene therapy, open-label, dose-escalation study of SPK-9001 [adeno-associated viral vector with human factor IX gene] in subjects with hemophilia B

(N Engl J Med 2017;377:2215-27)

NCT02484092 II B fidanacogene elaparvovec

 

(SPK-9001)

Active, not recruiting Spark Start November 2015

 

Completion 2019

N = 15
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors NCT03734588 I/II A SPK-8016 Recruiting Spark

 

Start 2016

 

Completion 2019

N = 30
A Phase I/II open-label safety and dose-finding study of adeno-associated virus (AAV) rh10-mediated gene transfer of human factor IX in adults with moderate/severe to severe hemophilia B

 

NCT02618915 I/II B DTX101

(now known as BAY2599023)

Terminated

(not due to safety concerns)

Dimension Start 2016

 

Ended 2017

N = 6 elderly
GO-8: Gene therapy for haemophilia A using a novel serotype 8 capsid pseudotyped adeno-associated viral vector encoding factor VIII-V3

 

(product is licensed to Biomarin)

NCT03001830 I A AAV2/8-HLP-FVIII-V3 Recruiting University College, London

 

St Jude Children’s Research Hospital

 

Start 2017

 

Completion 2019 (2034 for secondary outcomes)

 

N = 18
Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A (also known as Alta)

 

NCT03061201 II A giroctocogene fitelparvovec

(SB-525, PF-07055480)

Recruiting Pfizer Start 2017

 

Completion July 2024

N = 13
A Factor IX Gene Therapy Study (FIX-GT, also known as B-AMAZE)

 

NCT03369444 I B FLT180a

(AAVS3 vector)

Recruiting University College, London

 

Freeline

 

Start 2017

 

Completion 2021

 

N = 24
A Phase 3 open-label, single-arm study to evaluate the efficacy and safety of BMN 270, an adeno-associated virus vector-mediated gene transfer of human factor VIII in hemophilia A patients with residual FVIII levels ≤ 1 IU/dL receiving prophylactic FVIII infusions(also known as GENEr8-1,BMN 270-301) ) NCT03370913 III A valoctocogene roxaparvovec

 

6E13 vg/kg

Recruiting Biomarin Start Dec 2017

 

Completion 2022 (2023 for secondary outcomes)

N = 134
Phase 3 study to evaluate efficacy/safety of valoctocogene roxaparvovec an AAV vector-mediated gene transfer of hFVIII at a dose of 4E13vg/kg in hemophilia A patients with residual FVIII levels ≤1IU/dL receiving prophylactic FVIII infusions

(also known as GENEr8-2, BMN270-302)

 

NCT03392974 III A valoctocogene roxaparvovec

 

4E13vg/kg

Recruiting

 

Biomarin Start March 2018

 

Completion 2022 (2024 for secondary outcomes)

 

N = 40
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3)

 

NCT04323098 III A valoctocogene roxaparvovec

 

6E13 vg/kg with prophylactic corticosteroids

 

Not yet recruiting Biomarin Start June 2020

 

Completion December 2025

N = 20
A Phase 1/2 safety, tolerability, and efficacy study of valoctocogene roxaparvovec, an adeno-associated virus vector-mediated gene transfer of human factor VIII in hemophilia A patients with residual FVIII levels ≤ 1 IU/dL and pre-existing antibodies against AAV5

 

NCT03520712 I/II A valoctocogene roxaparvovec

 

6E13 vg/kg

Enrolling by invitation Biomarin Start May 2018

 

Completion 2024

N = 10
Phase III, open-label, single-dose, multi-center, multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B (HOPE-B)

 

NCT03569891 III B etranacogene dezaparvovec

 

(AAV5-hFIXco-Padua, AMT-061)

Recruiting UniQure Start June 2018 (first dose early 2019)

 

Completion 2020 (2024 for secondary outcomes)

N = 56
Phase IIb, open-label, single-dose, single-arm, multi-center trial to confirm the factor IX activity level of the serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B NCT03489291 IIb B etranacogene dezaparvovec

 

(AAV5-hFIXco-Padua,  (AMT-061)

Active, not recruiting UniQure Start July 2018

 

Completion Oct 2018 (2023 for secondary outcomes)

N = 3
A long-term follow-up study of haemophilia B patients who have undergone gene therapy NCT03641703 II/III B FLT180a Recruiting Freeline Start July 2018

Complete 2035

N = 50
A multi-center evaluation of the long-term safety and efficacy of SPK-8011 [adeno-associated viral vector with B-domain deleted human factor VIII gene] in males with hemophilia A NCT03432520 Observational cohort A SPK-8011 Enrolling by invitation Spark Start Aug 2018

 

Completion 2022

N = 100
Dose-finding study of SPK-8016 gene therapy in patients with hemophilia A to support evaluation in individuals with FVIII inhibitors NCT03734588 I/II A SPK-8016 Active, not recruiting Spark Start Nov 2018

 

Completion 2020

N = 30
Study to test the safety and how well patients with severe hemophilia a respond to treatment with BAY 2599023 (DTX 201), a drug therapy that delivers a healthy version of the defective factor viii gene into the nucleus of liver cells using an altered, non-infectious virus (AAV) as a “shuttle”. NCT03588299 I/II A BAY2599023 (DTX201) Recruiting Bayer Start Nov 2018

 

Completion 2022

(2026 for secondary outcomes)

 

N = 30
Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults (AFFINE) NCT04370054 III A giroctocogene fitelparvovec

(SB-525, PF-07055480)

Recruiting Pfizer Started August 2020

 

Completion October 2026

 

N = 63
BENEGENE 2. A study to evaluate the efficacy and safety of factor IX gene therapy with PF-06838435 in adult males with moderately severe to severe hemophilia B. NCT03861273 III B fidanacogene elaparvovec Recruiting Pfizer, Spark Started July 2019 N = 55
Hematopoietic stem cell transplantation gene therapy for treatment of severe hemophilia A. (ET3-201) NCT04418414 I A CD68-ET3 lentiviral vector Not yet recruiting (Sept 2020) Expression Therapeutics February 2021 N = 7